- Home
- NKTR vs PCRX Comparison
NKTR vs PCRX Comparison
Compare NKTR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- PCRX
- Stock Information
- Founded
- NKTR 1990
- PCRX 2006
- Country
- NKTR United States
- PCRX United States
- Employees
- NKTR N/A
- PCRX N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- NKTR Health Care
- PCRX Health Care
- Exchange
- NKTR Nasdaq
- PCRX Nasdaq
- Market Cap
- NKTR 1.1B
- PCRX 1.2B
- IPO Year
- NKTR 1994
- PCRX 2011
- Fundamental
- Price
- NKTR $54.35
- PCRX $23.24
- Analyst Decision
- NKTR Strong Buy
- PCRX Strong Buy
- Analyst Count
- NKTR 5
- PCRX 6
- Target Price
- NKTR $89.00
- PCRX $33.83
- AVG Volume (30 Days)
- NKTR 684.3K
- PCRX 740.7K
- Earning Date
- NKTR 11-06-2025
- PCRX 11-06-2025
- Dividend Yield
- NKTR N/A
- PCRX N/A
- EPS Growth
- NKTR N/A
- PCRX N/A
- EPS
- NKTR N/A
- PCRX 0.47
- Revenue
- NKTR $62,600,000.00
- PCRX $716,791,000.00
- Revenue This Year
- NKTR N/A
- PCRX $7.27
- Revenue Next Year
- NKTR N/A
- PCRX $10.18
- P/E Ratio
- NKTR N/A
- PCRX $48.91
- Revenue Growth
- NKTR N/A
- PCRX 3.14
- 52 Week Low
- NKTR $6.48
- PCRX $16.29
- 52 Week High
- NKTR $66.92
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- NKTR 44.64
- PCRX 50.60
- Support Level
- NKTR $52.50
- PCRX $23.62
- Resistance Level
- NKTR $61.81
- PCRX $24.95
- Average True Range (ATR)
- NKTR 3.62
- PCRX 1.29
- MACD
- NKTR -0.51
- PCRX 0.16
- Stochastic Oscillator
- NKTR 19.45
- PCRX 62.85
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.